Bellerophon plunges after lead drug flops in study; Leon-nanodrugs raises €18.5M;

@FierceBiotech: Cutting-edge research centers back Deerfield's $550M biotech venture fund. Story | Follow @FierceBiotech

@JohnCFierce: This just in, $SNY has decided to outsource all pipeline work and restrict R&D effort to writing checks. $REGN $ALNY | Follow @JohnCFierce

@DamianFierce: Marc Beer resignation PR includes a line about continuing "the company's commitment to high integrity and ethics." | Follow @DamianFierce

> Shares of Bellerophon Therapeutics plunged 60% after the biotech reported that its injectable heart drug--bioabsorbable cardiac matrix, or BCM--failed in a study. Story

> Germany's leon-nanodrugs raised €18.5 million in Series A financing. Release

> The FDA has green-lighted FibroGen's NDA for FG-3019 in patients with Duchenne muscular dystrophy. Release

> France's Guerbet is buying Mallinckrodt's contrast media and delivery systems business. Release

Medical Device News

@FierceMedDev: Docs dole out recs for reducing fetal ultrasound procedures in the U.S. Story | Follow @FierceMedDev

@EmilyWFierce: #FDA launches probe into safety of common MRI contrast agent. Article | Follow @EmilyWFierce

> Cepheid readies for 2016 launch of point-of-care molecular Dx system for use anywhere. More

> Micro-cap Nephros secures up to $10M to back its alternative to hemodialysis. Story

Pharma News

@FiercePharma: $BMY CEO talks up immuno-oncology space, coming hep C competition in Japan. Article | Follow @FiercePharma

@EricPFierce: ICYMI: Lupin lands its first US manufacturing site with $880M deal for GAVIS, 6-year-old NJ firm. More | Follow @EricPFierce

@CarlyHFierce: About that brand/generics hybrid thing? Make that brands only, Allergan says with Teva deal. News | Follow @CarlyHFierce

> Pfizer lifts guidance as Prevnar, Ibrance trigger Q2 beats. More

> Hikma shells out $2.65B for Boehringer's U.S. generics business. Story

Drug Delivery News

> IPOs: EyeGate tries again following deal with Valeant, Parkinson's specialist to debut soon. More

> Alnylam launches trial of one of its RNAi candidates. Article

> Pill holds a ring-shaped device that could deliver drugs to the stomach long-term. Story

> ASU team offers precise DNA origami technique with novel shapes and delivery potential. More

> Ra Pharma gets $58.5M to challenge a rare disease's intravenous incumbent. Article

Pharma Manufacturing News

> Avista Pharma snaps up NC manufacturing facility from rival Scynexis. Report

> Teva expands recall of cancer drug Adrucil. Story

> Androxy returns to market after 9-month lapse. News

> EU ban on more than 700 drugs set for Aug. 21. Item

> Hospira recall of ketorolac now close to 40 million vials. Article

Pharma Asia News

> Fallout from India's GVK means $1B lost in drug exports by March 2016. News

> Trans-Pacific Partnership impasse on data exclusivity for biologics softens. Story

> Roche COO O'Day highlights emerging markets trends on Q2 call. More

> Eli Lilly execs on Q2 call discuss Japan opportunities, China slowdown. Article

> EU-wide ban starts Aug. 21 on 700-plus drugs tested by India's GVK Bio Sciences. Report

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.